Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Van Gogh Study of pardoprunox adjunct to L-dopa in Parkinson's disease with motor fluctuations
2007-001095-36Phase 3Terminated
- Sponsor
- Solvay
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pardoprunox in Parkinson's disease (PD) (3 arms), sponsored by Solvay. Primary endpoint: Change in OFF-time. Started Feb 2008; status: terminated.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2007-001095-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001095-36.